--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
AMENDMENT NO. 1 TO
FORM 10-K
------------------------
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE YEAR ENDED OCTOBER 31, 2001
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
COMMISSION FILE NUMBER 0-45138
SYNOPSYS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 56-1546236
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
700 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW, CALIFORNIA 94043
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
(650) 584-5000
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT: NONE
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:
COMMON STOCK, $0.01 PAR VALUE
------------------------
PREFERRED SHARE PURCHASE RIGHTS
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]
The aggregate market value of voting stock held by non-affiliates of the
registrant as of January 5, 2002, was approximately $2,522,354,670.
On January 5, 2002, approximately 60,543,491 shares of the registrant's
Common Stock, $0.01 par value, were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
None.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
EXPLANATORY NOTE
This Amendment No. 1 to the Registrant's Annual Report on Form 10-K for the
fiscal year ended October 31, 2001 is being filed in order to submit the
information required to be included in Part III thereof within the period
required by General Instruction G(3) to Form 10-K. The Registrant will also
include this information in its proxy statement for its 2002 Annual Meeting of
Stockholders.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
Set forth below is information regarding the directors, including
information furnished by them as to principal occupations, certain other
directorships held by them, any arrangements pursuant to which they were
selected as directors and their ages as of January 31, 2002.
YEAR FIRST
NAME AGE ELECTED DIRECTOR
---- ---- ----------------
Aart J. de Geus............................................. 47 1986
Andy D. Bryant.............................................. 51 1999
Chi-Foon Chan............................................... 52 1998
Bruce R. Chizen............................................. 46 2001
Deborah A. Coleman.......................................... 49 1995
A. Richard Newton........................................... 50 1987; 1995
Sasson Somekh............................................... 55 1999
Steven C. Walske............................................ 49 1991
BACKGROUND OF DIRECTORS
DR. AART J. DE GEUS co-founded Synopsys and currently serves as Chief
Executive Officer and Chairman of the Board of Directors. Since the inception of
Synopsys in December 1986, he has held a variety of positions, including Senior
Vice President of Engineering and Senior Vice President of Marketing. From 1986
to 1992, Dr. de Geus served as Chairman of the Board. He served as President
from 1992 to 1998. Dr. de Geus has served as Chief Executive Officer since
January 1994 and has held the additional title of Chairman of the Board since
February 1998. He has served as a Director since 1986. From 1982 to 1986 Dr. de
Geus was employed by General Electric Corporation, where he was the Manager of
the Advanced Computer-Aided Engineering Group. Dr. de Geus holds an M.S.E.E.
from the Swiss Federal Institute of Technology in Lausanne, Switzerland and a
Ph.D. in electrical engineering from Southern Methodist University.
ANDY D. BRYANT has been a Director of Synopsys since January 1999 and
currently serves as Executive Vice President and Chief Financial and Enterprise
Services Officer of Intel Corporation, with responsibility for financial
operations, human resources, information technology and e-business functions and
activities worldwide. Mr. Bryant joined Intel in 1981 as Controller for the
Commercial Memory Systems Operation and in 1983 became Systems Group Controller.
In 1987 he was promoted to Director of Finance for the corporation and was
appointed Vice President and Director of Finance of the Intel Products Group in
1990. Mr. Bryant became CFO in February of 1994 and was promoted to Senior Vice
President in January 1999. Mr. Bryant expanded his role to Chief Financial and
Enterprise Services Officer in December 1999. He was promoted to Executive Vice
President in January 2001. Prior to joining Intel, he held positions in finance
at Ford Motor Company and Chrysler Corporation. Mr. Bryant holds a B.A. in
economics from the University of Missouri and an M.B.A. in finance from the
University of Kansas. Mr. Bryant is a director of Convera Corporation, a
provider of content management solutions.
DR. CHI-FOON CHAN joined Synopsys as Vice President of Application
Engineering & Services in May 1990. Since April 1997 he has served as Chief
Operating Officer and since February 1998 he has held the additional title of
President. Dr. Chan also became a Director of Synopsys in February 1998. From
September 1996 to February 1998 he served as Executive Vice President, Office of
the President. From February 1994 until April 1997 he served as Senior Vice
President, Design Tools Group and from October 1996 until April 1997 as Acting
Senior Vice President, Design Re-Use Group. Additionally, he has held the titles
of Vice President, Engineering and General Manager, DesignWare Operations and
Senior Vice President, Worldwide Field Organization. From March 1987 to May
1990, Dr. Chan was employed by NEC Electronics, where his last position was
General Manager, Microprocessor Division. From 1977 to 1987, Dr. Chan held a
number of senior engineering positions at Intel Corporation. Dr. Chan holds an
M.S. and Ph.D. in computer engineering from Case Western Reserve University.
1
BRUCE R. CHIZEN has been a Director of Synopsys since April 2001. Mr.
Chizen has served as President of Adobe Systems Incorporated, a provider of
graphic design, publishing, and imaging software for Web and print production,
since April 2000 and as Chief Executive Officer since December 2000. He joined
Adobe Systems in August 1994 as Vice President and General Manager, Consumer
Products Division and in December 1997 became Senior Vice President and General
Manager, Graphics Products Division. In August 1998 Mr. Chizen was promoted to
Executive Vice President, Products and Marketing. From November 1992 to February
1994 he was Vice President and General Manager, Claris Clear Choice for Claris
Corp., a wholly-owned subsidiary of Apple Computer. He is a Director of Adobe
Systems Incorporated and Viewpoint Corporation, a provider of advanced 3D
product visualization and marketing solutions.
DEBORAH A. COLEMAN has been a Director of Synopsys since November 1995. Ms.
Coleman is co-founder and currently General Partner of SmartForest Ventures in
Portland, Oregon. Ms. Coleman was Chairman of the Board of Merix Corporation, a
manufacturer of printed circuit boards, from May 1994, when it was spun off from
Tektronix, Inc., until September 2001. She also served as Chief Executive
Officer of Merix from May 1994 to September 1999 and as President from March
1997 to September 1999. Ms. Coleman joined Merix from Tektronix, a diversified
electronics corporation, where she served as Vice President of Materials
Operations, responsible for worldwide procurement, distribution, component
engineering and component manufacturing operation. Prior to joining Tektronix in
November 1992, Ms. Coleman was with Apple Computer, Inc. for eleven years, where
she held several executive positions, including Chief Financial Officer, Chief
Information Officer and Vice President of Operations. She is a Director of
Applied Materials, Inc., a manufacturer of semiconductor fabrication equipment.
DR. A. RICHARD NEWTON has been a Director of Synopsys since January 1995.
Previously, Dr. Newton was a Director of Synopsys from January 1987 to June
1991. Dr. Newton has been a Professor of Electrical Engineering and Computer
Sciences at the University of California at Berkeley since 1979 and is currently
Dean of the College of Engineering. From July 1999 to June 2000, Dr. Newton was
Chair of the Electrical Engineering and Computer Sciences Department. Since 1988
Dr. Newton has acted as a Venture Partner with Mayfield Fund, a venture capital
partnership, and has contributed to the evaluation and development of over two
dozen new companies. From November 1994 to July 1995 he was acting President and
Chief Executive Officer of Silicon Light Machines, a private company which has
developed display systems based on the application of micromachined silicon
light-valves. Dr. Newton is also a Director of Simplex Solutions, Inc., which
provides software and services for integrated circuit design and verification.
DR. SASSON SOMEKH has been a Director of Synopsys since January 1999. He is
Executive Vice President of Applied Materials, Inc., a manufacturer of
semiconductor fabrication equipment. From December 1993 to November 2000, Dr.
Somekh served as Senior Vice President. Dr. Somekh served as Group Vice
President from 1990 to 1993. Prior to that, he was a divisional Vice President.
Dr. Somekh joined Applied Materials in 1980 as a Project Manager.
STEVEN C. WALSKE has been a Director of Synopsys since December 1991. Mr.
Walske has been Chief Business Strategist of Parametric Technology Corporation,
a supplier of software products for mechanical computer aided engineering, since
June 2000 and served as Chairman, Chief Executive Officer and a Director from
August 1994 until June 2000. From December 1986 to August 1994 Mr. Walske served
as President and Chief Executive Officer of that company.
There are no family relationships among any executive officers, directors
or persons chosen or nominated to become executive officers or directors of
Synopsys.
2
DIRECTORS' COMPENSATION
During fiscal 2001, each non-employee board of directors member was paid an
annual retainer of $8,000 and $1,000, respectively, for each board of directors
or board of directors committee meeting attended, plus expenses.
In addition, non-employee board of directors members receive automatic
option grants under the 1994 Non-Employee Directors Stock Option Plan, which in
this document we refer to as the "Directors Plan." As of the date of this joint
proxy statement/prospectus, all six non-employee Synopsys board of directors
members were eligible to participate in the Directors Plan.
During fiscal 2001, directors Andy D. Bryant, Bruce R. Chizen, Deborah A.
Coleman, A. Richard Newton, Sasson Somekh and Steven C. Walske each received
automatic grants of options to purchase 10,000 Synopsys common shares at an
exercise price of $50.69 per share for Synopsys board of directors service
during the year. In addition, during fiscal 2001, Mr. Chizen received options to
purchase 9,166 Synopsys common shares, at an exercise price of $61.37, and Ms.
Coleman and Messrs. Bryant, Newton, Somekh and Walske each received options to
purchase 10,000 Synopsys common shares for service on Synopsys board of
directors committees at an exercise price of $50.69. Mr. Chizen also received an
automatic grant of options to purchase 20,000 Synopsys common shares at an
exercise price of $50.69 per share for his initial Synopsys board of directors
service.
During fiscal 2001, Dr. Newton provided consulting services to Synopsys,
for which he was paid $150,000. Under Synopsys' agreement with Dr. Newton, at
Synopsys' request, Dr. Newton provides advice concerning long-term technology
strategy and industry development issues, as well as providing assistance in
identifying opportunities for partnerships with academia.
BACKGROUND OF EXECUTIVE OFFICERS
Information regarding executive officers of the Company is included in Part
I of this Annual Report.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Exchange Act requires Synopsys' directors, officers
and greater than ten percent beneficial owners of its shares to file reports of
ownership and changes in ownership with the SEC. Directors, officers and greater
than ten percent stockholders are required by SEC regulations to furnish
Synopsys with copies of all Section 16(a) forms they file.
Based solely upon its review of the copies of the Forms 3, 4 and 5 received
by Synopsys and/or written representations from certain reporting persons,
Synopsys believes that each of its directors, officers, and greater than ten
percent beneficial owners of its shares during the fiscal year ended November 3,
2001 has complied with all filing requirements applicable to such persons during
such fiscal year, except that an amended Form 4 was filed on behalf of Vicki
Andrews to reflect the sale of additional shares sold as part of a previously
reported transaction, which additional sale was not timely reported.
3
ITEM 11. EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION AND OTHER MATTERS
The following table sets forth the compensation earned by (1) Synopsys'
Chief Executive Officer and (2) each of the other four most highly compensated
executive officers whose compensation for fiscal 2001 exceeded $100,000, which
in this document we collectively refer to as the "named executive officers," for
services rendered in all capacities to Synopsys during the last three fiscal
years.
SUMMARY COMPENSATION TABLE
LONG-TERM
COMPENSATION:
ANNUAL SECURITIES
COMPENSATION($) AWARDS ALL OTHER
------------------- UNDERLYING COMPENSATION
NAME AND POSITION YEAR(1) SALARY BONUS OPTIONS(#) ($)(2)
----------------- ------- ------- -------- ------------- ------------
Aart J. de Geus.................... 2001 400,000 575,000 85,500 1,830
Chief Executive Officer and 2000 430,769 600,000 731,000 1,855
Chairman of the Board 1999 375,000 681,690 254,700 1,953
Chi-Foon Chan...................... 2001 400,000 575,000 71,000 2,588
President and Chief Operating 2000 430,769 600,000 623,000 2,493
Officer 1999 375,000 681,690 199,200 1,653
Vicki L. Andrews................... 2001 289,423 611,396(3) 60,500 9,544
Senior Vice President 2000 287,500 568,256(4) 179,000 9,826
World Wide Sales
Robert B. Henske................... 2001 364,423 350,000 60,500 1,825
Senior Vice President and 2000(5) 175,000 232,000 340,000 160
Chief Financial Officer
Steven K. Shevick.................. 2001 241,538 175,000 17,500 1,871
Vice President, Investor 2000 236,154 160,984 100,000 1,833
Relations and Legal,
General Counsel
---------------
(1) During fiscal 1999, Synopsys had a fiscal year that ended on the last
Saturday of September. In July 1999, Synopsys changed its fiscal year end to
the last Saturday in October. As a result, salary data for fiscal 2000
includes the 13-month period ended October 28, 1999.
(2) Amounts in this column reflect premiums paid for group term life insurance,
Synopsys 401(k) contributions and, in the case of Ms. Andrews only, car
allowances.
(3) Ms. Andrews' 2001 bonus consists of commissions of $150,000, a variable
bonus of $296,260, a relocation bonus of $160,000 and a special bonus of
$5,136.
(4) Ms. Andrews' 2000 bonus consists of commissions of $318,096 and a variable
bonus of $250,160.
(5) Mr. Henske commenced employment with Synopsys on May 10, 2000.
4
STOCK OPTION GRANTS
The following table sets forth further information regarding individual
grants of options for Synopsys common shares during fiscal 2001 for each of the
named executive officers. All grants for each of the named executive officers
were made pursuant to the 1992 stock option plan. In accordance with the rules
of the SEC, the table sets forth the hypothetical gains or "option spreads" that
would exist for the options at the end of their respective ten-year terms based
on assumed annualized rates of compound stock price appreciation of 5% and 10%
from the dates the options were granted to the end of their respective option
terms. Actual gains, if any, on option exercises are dependent on the future
performance of the Synopsys common shares and overall market conditions. There
can be no assurance that the potential realizable values shown in this table
will be achieved. No stock appreciation rights were granted to such officers
during fiscal 2001.
OPTION GRANTS IN LAST FISCAL YEAR
POTENTIAL REALIZABLE
VALUE AT ASSUMED ANNUAL
NUMBER OF PERCENT OF RATES OF STOCK PRICE
SECURITIES TOTAL OPTIONS APPRECIATION FOR
UNDERLYING GRANTED TO EXERCISE OR OPTION TERM($)
OPTIONS EMPLOYEES BASE PRICE EXPIRATION -----------------------
NAME GRANTED(1) FISCAL 2001(2) ($/SHARE) DATE 5% 10%
---- ---------- -------------- --------------- ------------------- ---------- ----------
Aart J. de Geus...... 85,500 1.47 $47.44 - $61.37 2/28/11 - 8/28/11 $2,930,209 $7,425,724
Chi-Foon Chan........ 71,000 1.22 $47.44 - $61.37 2/28/11 - 8/28/11 $2,432,192 $6,163,652
Vicki L. Andrews..... 60,500 1.04 $47.44 - $61.37 2/28/11 - 8/28/11 $2,084,176 $5,281,710
Robert B. Henske..... 60,500 1.04 $47.44 - $61.37 2/28/11 - 8/28/11 $2,084,176 $5,281,710
Steven K. Shevick.... 17,500 0.30 $47.44 - $61.37 2/28/11 - 8/28/11 $ 600,604 $1,522,048
---------------
(1) Sum of all option grants made during the fiscal year to such person. Options
become exercisable ratably in a series of monthly installments over a
four-year period from the grant date, assuming continued service to
Synopsys, subject to acceleration under certain circumstances involving a
change in control of Synopsys. Each option has a maximum term of 10 years,
subject to earlier termination upon the optionee's cessation of service.
(2) Based on aggregate options to acquire 5,809,892 Synopsys common shares
granted in fiscal 2001.
OPTION EXERCISES AND YEAR-END VALUES
The following table sets forth, for each of the named executive officers,
each exercise of stock options during fiscal 2001 and the year-end value of
unexercised options.
No stock appreciation rights were exercised during such fiscal year by the
named executive officers, and no stock appreciation rights were outstanding at
the end of the fiscal year.
5
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR-END OPTION
VALUES
SHARES NUMBER OF UNEXERCISED VALUE OF IN-THE-MONEY
ACQUIRED VALUE OPTIONS AT FY-END OPTIONS AT FY-END($)(2)
ON REALIZED --------------------------- ---------------------------
NAME EXERCISE (1) EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
---- ----------- -------- ----------- ------------- ----------- -------------
Aart J. de Geus............. -- -- 967,503 654,697 $9,868,495 $5,464,579
Chi-Foon Chan............... -- -- 549,005 547,195 $4,430,172 $4,427,467
Vicki L. Andrews............ 11,000 $305,335 69,049 174,617 $ 689,694 $1,509,669
Robert B. Henske............ -- -- 124,374 276,126 $1,314,625 $2,563,045
Steven K. Shevick........... -- -- 74,665 87,335 $ 730,765 $ 738,265
---------------
(1) Market value at exercise less exercise price.
(2) Market value of underlying securities on November 2, 2001 ($47.86) minus the
exercise price.
EMPLOYMENT CONTRACTS, TERMINATION OF EMPLOYMENT ARRANGEMENTS AND CHANGE OF
CONTROL AGREEMENTS
Under Synopsys' 1992 stock option plan, in the event of certain changes in
the ownership or control of Synopsys involving a "Corporate Transaction," which
includes an acquisition of Synopsys by merger or asset sale, all outstanding
options under the 1992 stock option plan will automatically become exercisable,
unless the option is assumed by the successor corporation, or parent thereof, or
replaced by a comparable option to purchase shares of the capital stock of the
successor corporation, or parent thereof.
In addition, in the event of a successful hostile tender offer for more
than 50% of the outstanding Synopsys common shares or a change in the majority
of the Synopsys board of directors as a result of one or more contested
elections for membership on the Synopsys board of directors, the administrator
of the 1992 stock option plan has the authority to provide for the acceleration
of vesting of the Synopsys common shares subject to outstanding options under
the 1992 stock option plan.
Synopsys has entered into Employment Agreements, effective October 1, 1997,
with its Chief Executive Officer and its President and an Employment Agreement
with its Chief Financial Officer, effective May 10, 2000. Each Employment
Agreement provides that if the executive is terminated involuntarily other than
for cause within 24 months of a change of control, (a) the executive will be
paid an amount equal to two times the sum of the executive's annual base pay
plus target cash incentive, plus the cash value of the executive's health
benefits for the next 18 months and (b) all stock options held by the executive
will immediately vest in full. If the executive is terminated involuntarily
other than for cause in any other situation, the executive will receive a cash
payment equal to the sum of the executive's annual base pay for one year plus
the target cash incentive for such year, plus the cash value of the executive's
health benefits for 12 months. The terms "involuntary termination," "cause" and
"change of control" are defined in each Employment Agreement, each of which is
filed with the SEC.
6
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information with respect to the
beneficial ownership of Synopsys common shares as of January 21, 2002 by (1)
each person known by Synopsys to own beneficially more than five percent of the
outstanding Synopsys common shares on that date, (2) each Synopsys director, (3)
each of the named executive officers and (4) all Synopsys directors and current
executive officers as a group.
SHARES OF COMMON STOCK
BENEFICIALLY OWNED
------------------------
PERCENTAGE
NAME OF BENEFICIAL OWNER(1) NUMBER OWNERSHIP
--------------------------- --------- ----------
FMR Corp.................................................... 6,503,587(2) 10.73%
82 Devonshire Street
Boston, MA 02109
J. & W. Seligman & Co. Incorporated......................... 6,148,610(2) 10.14%
100 Park Avenue, 8th Floor
New York, NY 10017
Blum Capital Partners, L.P.(3).............................. 4,020,900(2) 6.63%
909 Montgomery Street, Suite 400
San Francisco, CA 94133-4625
Vicki L. Andrews............................................ 94,361(4) *
Andy D. Bryant.............................................. 73,749(5) *
Chi-Foon Chan............................................... 672,697(6) 1.11%
Bruce R. Chizen............................................. 39,166(7) *
Deborah A. Coleman.......................................... 40,000(8) *
Aart J. de Geus............................................. 1,388,725(9) 2.29%
Robert B. Henske............................................ 175,577(10) *
A. Richard Newton........................................... 80,994(11) *
Steven K. Shevick........................................... 85,701(12) *
Sasson Somekh............................................... 93,333(13) *
Steven C. Walske............................................ 96,016(14) *
All directors and current executive officers as a group (11
persons).................................................. 2,840,319(15) 4.69%
---------------
* Less than 1%
(1) The persons named in the table above have sole voting and investment power
with respect to all Synopsys common shares shown as beneficially owned by
them, subject to community property laws where applicable and the
information contained in the footnotes of this table.
(2) Based upon filings made with the SEC.
(3) According to Amendment No. 1 to Schedule 13D filed by Blum Capital, L.P. on
September 24, 2001, voting and investment power concerning these shares is
held solely by Blum Capital Partners L.P., a California limited
partnership, RCBA GB, L.L.C., a Delaware limited liability company, and
Blum Strategic GP II, L.L.C., a Delaware limited liability company.
(4) Includes options to purchase 94,135 Synopsys common shares exercisable by
Ms. Andrews within 60 days of January 21, 2002.
(5) Consists of options to purchase 73,749 Synopsys common shares exercisable
by Mr. Bryant within 60 days of January 21, 2002.
(6) Includes options to purchase 640,915 Synopsys common shares exercisable by
Dr. Chan within 60 days of January 21, 2002.
(7) Consists of options to purchase 39,166 Synopsys common shares exercisable
by Mr. Chizen within 60 days January 21, 2002.
(8) Consists of options to purchase 40,000 Synopsys common shares exercisable
by Ms. Coleman within 60 days of January 21, 2002.
7
(9) Includes options to purchase 1,077,143 Synopsys common shares exercisable
by Dr. de Geus within 60 days of January 21, 2002.
(10) Includes options to purchase 165,125 Synopsys common shares exercisable by
Mr. Henske within 60 days of January 21, 2002.
(11) Includes options to purchase 75,916 Synopsys common shares exercisable by
Dr. Newton within 60 days of January 21, 2002.
(12) Includes options to purchase 83,842 Synopsys common shares exercisable by
Mr. Shevick within 60 days of January 21, 2002.
(13) Includes options to purchase 80,833 Synopsys common shares exercisable by
Dr. Somekh within 60 days of January 21, 2002.
(14) Includes options to purchase 95,916 Synopsys common shares exercisable by
Mr. Walske within 60 days of January 21, 2002.
(15) Includes options to purchase 2,466,740 Synopsys common shares exercisable
by directors and current executive officers within 60 days of January 21,
2002.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
See Item 10, "Directors and Executive Officers of the Registrant-Directors'
Compensation."
8
SIGNATURES
Pursuant to the requirements of section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this amendment to be signed
on its behalf by the undersigned, thereunto duly authorized, in Mountain View,
State of California, on this 28th day of February, 2002.
SYNOPSYS, INC.
By: /s/ ROBERT B. HENSKE
------------------------------------
Robert B. Henske
Senior Vice President, Finance and
Operations,
and Chief Financial Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this
amendment has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated:
SIGNATURE TITLE DATE
--------- ----- ----
/s/ AART J. DE GEUS* Chief Executive Officer February 28, 2002
----------------------------------------------------- (Principal Executive Officer)
Aart J. de Geus and Chairman of the
Board of Directors
/s/ CHI-FOON CHAN* President, Chief Operating February 28, 2002
----------------------------------------------------- Officer and Director
Chi-Foon Chan
/s/ BRUCE R. CHIZEN Director February 28, 2002
-----------------------------------------------------
Bruce R. Chizen
/s/ ANDY D. BRYANT* Director February 28, 2002
-----------------------------------------------------
Andy D. Bryant
/s/ DEBORAH A. COLEMAN* Director February 28, 2002
-----------------------------------------------------
Deborah A. Coleman
/s/ HARVEY C. JONES, JR.* Director February 28, 2002
-----------------------------------------------------
Harvey C. Jones, Jr.
/s/ A. RICHARD NEWTON* Director February 28, 2002
-----------------------------------------------------
A. Richard Newton
/s/ SASSON SOMEKH* Director February 28, 2002
-----------------------------------------------------
Sasson Somekh
/s/ STEVEN C. WALSKE* Director February 28, 2002
-----------------------------------------------------
Steven C. Walske
* /s/ ROBERT B. HENSKE
-----------------------------------------------------
*By: Robert B. Henske, Attorney-in-fact
9